Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Submit your abstract to the leading global meeting dedicated to precision oncology.
Browse the high quality scientific and educational content from ESMO Breast Cancer 2023
Learn how the ESMO Guidelines can help in real-world clinical settings. Register now and get your questions answered by the experts
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs
Technology promises to improve understanding of cancer risk and lesion biology, but clear regulation is urged to implement innovation in cancer screening programmes
Lessons learned from the use of second-generation antibody–drug conjugates (ADCs) in breast cancer can direct treatment in other tumour types
In her keynote lecture, recipient of the ESMO Breast Cancer Award 2023, Prof. Sara A. Hurvitz talks of the need to challenge accepted paradigms to progress clinical research
Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases
Data from two studies improve knowledge of how to treat patients with a disease harbouring this molecular alteration and how to monitor response to treatment
Final OS analysis of the phase III CONTACT-01 trial reports negative results for immunotherapy versus docetaxel in patients progressing on checkpoint inhibitors plus chemotherapy
Additional exploratory analyses of the phase III CheckMate 816 trial reveal that event-free survival at 3 years is not influenced by surgical parameters and suggest that tumour inflammation may be a useful predictive biomarker
It is intended for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic treatment
An inherited cancer-predisposition mechanism distinct from that of mutations affecting tumour-suppressor proteins and oncoproteins
Findings from genomic analysis in a rapid autopsy cohort study
Findings from 2-year analysis of CodeBreaK 100 study
Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer
Findings from the CUTALLO study
The revision of the EU’s Asbestos at Work Directive is set to enhance the protection of workers in Europe against asbestos, which is a highly dangerous carcinogenic substance. ESMO’s efforts to establish a robust exposure limit of 1,000 fibres per m3 and use more modern measuring methods are reflected in the European Parliament’s position.
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs
Extended indication concerns the treatment of melanoma in adolescents 12 years of age and older
It is intended for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic treatment
An inherited cancer-predisposition mechanism distinct from that of mutations affecting tumour-suppressor proteins and oncoproteins
Findings from genomic analysis in a rapid autopsy cohort study
Findings from 2-year analysis of CodeBreaK 100 study
Findings from the CUTALLO study
Extended indication concerns the treatment of melanoma in adolescents 12 years of age and older
Findings from the DESTINY-Breast02 study
Findings from the SUNLIGHT study
Findings from the POSITIVE study
The new online tool comes in an interactive, concise, and updatable visual format to support practicing oncologists in the rapidly evolving medical field
The ESMO Breast Cancer Congress 2023, will be held onsite in Berlin, Germany, and online, through a virtual platform, between 11-13 May 2023
Adding immunotherapy to standard chemotherapy for first-line treatment of advanced or first recurrence of endometrial cancer significantly improves progression-free survival (PFS) compared to chemotherapy alone, with a promising early indication of improved overall survival (OS)
ESMO is pleased to announce a combination of brand-new and well-established events happening in March, tackling two specific areas of oncology, with leading experts discussing novel clinical data and the latest treatment options
A total of 1,261,990 people will die from cancer in 2023 in the EU (EU-27). A further 172,314 people will die from the disease in the UK, according to new research published in the leading cancer journal Annals of Oncology today
The ESMO Targeted Anticancer Therapies Congress 2023, the gathering focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development, will be held in Paris, France, on 6-8 March 2023.
The ESMO Gynaecological Cancers Congress 2023, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide an overview of the latest treatments as well as insights into the biology and biomarkers of ovarian, uterine, cervical and even rare gynaecological cancers.
The European Society for Medical Oncology (ESMO) has developed a quality of life (QoL) checklist that is now integral to the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) - a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
The ESMO Immuno-Oncology Congress 2022, an annual congress dedicated to the presentation and discussion of the latest scientific developments in this fast-moving field, will be held in person in Geneva, Switzerland, and virtually between 7-9 December.
ESMO launched the ESMO Living Guidelines, a new tool designed to make the ESMO Clinical Practice Guidelines (CPGs) easier to use in oncologists’ routine clinical practice and support optimal decision-making in a rapidly evolving medical field
The European Society for Medical Oncology (ESMO) has announced today that the 2023 ESMO Breast Cancer Award is bestowed to Sara A. Hurvitz for her remarkable contributions to breast cancer clinical and laboratory-based research
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced today that the 2023 Heine H. Hansen Award is conferred on Paul Baas for his outstanding contribution to thoracic oncology research
ESMO has announced today that the 2023 ESMO TAT Honorary Award is presented to Susan Bates
ESMO is pleased to announce that the nomination process for the 2023 ESMO Society Awards is now open.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
ESMO renews its support to World Cancer Day (WCD) joining the #CloseTheCareGap campaign led by the Union for International Cancer Control (UICC).
Andrés Cervantes started his two-year mandate as ESMO President on 1 January 2023.
From ESMO Breast Cancer 2023:
Patients given neoadjuvant atezolizumab alongside chemotherapy for stage II–III triple-negative breast cancer are more likely to achieve pathological complete response but do not have better survival
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Spain
United Arab Emirates
Netherlands
Spain
Switzerland
Portugal
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
